Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
Glucagon is used for the treatment of hypoglycemia, and glucagon receptor antagonists are under development for the treatment of type 2 diabetes. Moreover, glucagon-like peptide (GLP)-1 and GLP-2 receptor agonists appear to be promising therapies for the treatment of type 2 diabetes and intestinal disorders, respectively. This review discusses the physiological, pharmacological, and therapeutic actions of the proglucagon-derived peptides, with an emphasis on clinical relevance of the peptides for the treatment of human disease.
Sinclair
Elaine M
EM
Department of Medicine, Banting and Best Diabetes Centre, Toronto General Hospital and the University of Toronto, Toronto, Ontario, Canada.
Drucker
Daniel J
DJ
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D018819:Dipeptidyl Peptidase 4 / Q000187:drug effects; D004194:Disease; D005934:Glucagon / Q000031:analogs & derivatives* / Q000502:physiology / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1; D053767:Glucagon-Like Peptide 2; D000067757:Glucagon-Like Peptide-1 Receptor; D004763:Glucagon-Like Peptides / Q000502:physiology; D006801:Humans; D007410:Intestinal Diseases / Q000188:drug therapy; D010446:Peptide Fragments / Q000502:physiology / Q000627:therapeutic use; D010455:Peptides / Q000378:metabolism / Q000502:physiology* / Q000627:therapeutic use*; D052336:Proglucagon; D011480:Protease Inhibitors / Q000627:therapeutic use; D011498:Protein Precursors / Q000502:physiology / Q000627:therapeutic use; D018027:Receptors, Glucagon / Q000819:agonists / Q000502:physiology
C000593833:GLP1R protein, human; D053767:Glucagon-Like Peptide 2; D000067757:Glucagon-Like Peptide-1 Receptor; D010446:Peptide Fragments; D010455:Peptides; D011480:Protease Inhibitors; D011498:Protein Precursors; D018027:Receptors, Glucagon; D052336:Proglucagon; D004763:Glucagon-Like Peptides; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D018819:Dipeptidyl Peptidase 4